Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Clinical trial NCT01623349 · COMPLETED
Trial details
- NCT number
- NCT01623349
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-01
- Primary completion
- 2019-05-01
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.